The presentation, entitled: "SCIB1 ImmunoBody stimulates a potent T cell response that eradicates tumours and prevents recurrence", will be presented on Wednesday 30 March 2016 at 11.40am EDT at the congress in Washington DC.
Dr Brown is Scancell's clinical and scientific consultant on Immunotherapeutics.
Scancell's first ImmunoBody, SCIB1, is currently being evaluated in a Phase 1/2 clinical trial in patients with Stage III/IV melanoma. The latest data suggests that SCIB1 may have the potential to significantly extend survival times in patients, especially in those with resected disease.
Scancell is in the process of preparing a final clinical study report. A Phase 2 checkpoint inhibitor combination study of SCIB1 in melanoma is due to commence in 2017.
"We are delighted to be presenting an update on SCIB1 at the World Vaccine Congress, alongside some of the most distinguished companies in the immunotherapy field,” said Richard Goodfellow, joint chief executive officer of Scancell.
“Funds from the recently announced placing and the pending open offer will be used to further progress our ImmunoBody and Moditope platforms, including helping to fund our expanded SCIB1 clinical trial programme, which will be led by a team of leading US specialists," he added.